Medline eyes IPO
By HME News Staff
Updated 12:24 PM CST, Thu January 2, 2025
NORTHFIELD, Ill. – Medline has confidentially submitted a draft registration statement on Form S-1 to the U.S. Securities and Exchange Commission for a proposed initial public offering of its common stock.
The number of shares to be offered and the price range for the proposed offering have not yet been determined. The offering is subject to market and other conditions and the completion of the SEC's review process.
In 2021, Medline announced it had received outside investment from private equity firms Blackstone, Carlyle and Hellman & Friedman in a deal reportedly worth more than $30 billion. Since then, the company has since made multiple moves to strengthen its role as a strategic partner, including joining forces with Microsoft to address supply chain complexity.
In 2023, Medline promoted Jim Boyle to serve as CEO, and Jim Pigott as president & COO, culminating a five-year succession planning process.
Comments